Nitric oxide reversal of recurrent pulmonary hypertension and respiratory failure in an infant with CDH after successful ECMO therapy

Nitric oxide (NO) represents a new therapeutic modality for treating neonatal pulmonary hypertension and may obviate the need for extracorporeal membrane oxygenation (ECMO) in a number of cases of neonatal respiratory failure. Recently, the authors treated an infant with a congenital diaphragmatic h...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pediatric surgery 1995-05, Vol.30 (5), p.743-744
Main Authors: Dillon, P.W, Cilley, R.E, Hudome, S.M, Ozkan, E.N, Krummel, T.M
Format: Article
Language:English
Subjects:
Biological and medical sciences
Extracorporeal Membrane Oxygenation
Female
Hernia, Diaphragmatic - therapy
Hernias, Diaphragmatic, Congenital
Humans
Hypertension, Pulmonary - drug therapy
Infant, Newborn
Medical sciences
Pharmacology. Drug treatments
Recurrence
Respiration, Artificial
Respiratory Insufficiency - drug therapy
Respiratory system
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nitric oxide (NO) represents a new therapeutic modality for treating neonatal pulmonary hypertension and may obviate the need for extracorporeal membrane oxygenation (ECMO) in a number of cases of neonatal respiratory failure. Recently, the authors treated an infant with a congenital diaphragmatic hernia and pulmonary hypertension with NO on two separate occassions. During the initial period of stabilization, NO failed to reverse the pulmonary hypertension and prevent the development of progressive respiratory failure. After a successful course of ECMO, recurrent pulmonary hypertension developed that was successfully treated with continuous low-dose NO therapy for over 1 month. Prolonged administration of NO in varying doses titrated to clinical and echocardiographic parameters was well tolerated by the infant and prevented the need for a second run of ECMO.
ISSN:0022-3468
1531-5037
DOI:10.1016/0022-3468(95)90706-8